After all, we already know that being fat is bad for us. But understanding the molecular and genetic basis for obesity, and obesity related conditions, is the first step in developing effective treatments, and hopefully one day a cure. And this better understanding of obesity, combined with more effective drug discovery methods have already started to bear fruit. After the disappointing results of the recombinant leptin trials , early data on the drug Axokine , which will begin phase 3 testing this year, look much more promising. The human growth hormone fragment AOD-9604 is scheduled to begin phase 1 trials this month, and it looks like Famoxin will begin human testing later this year.
New gene explains the link between obesity and diabetes.
Fat cell defect may trigger insulin resistance. Chronic overeating and free radicals. Pregnancy and long-term weight gain. Raised inflammatory cytokines in obese patients. Effect of diet and exercise on leptin.